NASDAQ$JANX

Janux Therapeutics Inc · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Headline financials

Total Revenue

$380K

No prior period
EPS (adj)

-$0.06

Previous: -$0.11+49.5%
Net Income

-$2.28M

Previous: -$1.41M-61.6%
Operating Income

-$2.28M

Previous: -$826K-176.5%
Gross Profit

-$1.55M

Previous: -$549K-181.4%
R&D Expense

$1.93M

Previous: $549K+250.6%

Revenue & EPS history

Janux · Revenue · Quarterly

$380K

Q1 2021
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Revenue by segment

Janux · $1.06M total across 1 segment · Q2 2023

  • Collaboration revenue
    $1.06M-55.3%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports

Historical avg

+0.6%

Avg return

Earnings day

-1.5%

Avg return

5 days after

-5.5%

Avg return

30 days after

42%

8 / 19 earnings

Positive

+14.6%

Q3 2022

Best reaction

-11.0%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.6%-1.4%-8.8%
Q4 2025-1.4%+4.0%-4.5%
Q3 2025+3.9%+4.8%-40.1%
Q1 2025-0.8%+3.8%-2.8%
Q4 2024+2.7%-1.6%-9.1%
Q3 2024-1.9%-2.9%+17.6%
Q2 2024-1.1%-0.8%+11.8%
Q1 2024-11.0%-21.3%-31.5%
Q4 2023-1.6%-1.7%-13.5%
Q3 2023+5.9%-3.4%+50.7%
Q2 2023+5.1%+4.3%-11.6%
Q1 2023+1.1%-7.0%-3.5%
Q4 2022-2.5%-4.7%-4.9%
Q3 2022+14.6%+5.3%-9.8%
Q2 2022+1.0%-4.9%-3.2%
Q1 2022+6.1%+13.7%+10.0%
Q4 2021-6.0%-3.5%-17.1%
Q3 2021-1.6%-7.4%-23.9%
Q2 2021-1.0%-3.8%-9.9%
Q1 2021
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro